Clinical trial
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors…
NCT00030667 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030667 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood |
| Official title | A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma, Gastrointestinal Stromal Tumor, Lung Metastases, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis, pharmacological study |
| Enrollment | 100 |
| Start date | May 1, 2002 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | May 7, 2003 |
| Last update posted | Apr 15, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: